TrialNature medicine2023

Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.

Maja Di Rocco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.